TWi Biotechnology Selects Medidata’s Cloud-Based Platform to Advance Cutting-Edge Clinical Development
NEW YORK, N.Y. – February 11, 2015 – Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that its industry-leading technology platform has been adopted by TWi Biotechnology, Inc. A top biopharmaceutical company based in Taiwan, TWi Biotechnology selected the Medidata Clinical Cloud® to enhance the speed, quality and productivity of its novel clinical study on metabolic disorders.
“The Medidata platform has been broadly adopted globally and using it allows TWi to be more efficient, while ensuring investigative sites and clinical research coordinators are familiar and engaged with the technology,” said Dr. Calvin Chen, TWi Biotechnology’s president. “We’re pleased to be collaborating with Medidata as we work to address unmet medical needs and continue to provide innovative, high- quality treatments to patients worldwide.”
TWi Biotechnology is focused on developing innovative new therapies for unmet medical needs in the areas of metabolism, orphan diseases and dermatology. To optimize a Phase-II study on metabolic disorders, TWi Biotechnology is implementing Medidata’s cloud-based technology for electronic data capture and management (Medidata Rave®) and medical coding (Medidata Coder®). In addition to enhancing productivity through real-time data entry, Medidata’s technology solutions are providing TWi Biotechnology with better clinical trial oversight that leads to earlier, more informed decision-making opportunities.
“Emerging markets in Asia hold great promise for future growth in the life sciences industry,” said Takeru Yamamoto, Medidata’s managing director of the Asia-Pacific (APAC) region. “We’re thrilled that TWi has selected Medidata’s technology to power their important research, providing us with the opportunity to contribute to drug development activities in Taiwan-and across Asia-that have the potential to advance new therapies in areas of significant unmet need."
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
